COMING SOON: The Role of BCMA-Directed Therapy in Relapsed/Refractory Multiple Myeloma

During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Taiga Nishihori, MD, discussed the current outpatient administration model of cilta-cel among patients with relapsed/refractory multiple myeloma.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

A cohort study of the KarMMa-2 trial discovered durable responses in patients with high-risk multiple myeloma treated with ide-cel.

The CARTITUDE-4 study that found that treatment with cilta-cel led to a statistically significant and clinically meaningful improvement in overall survival among patients with relapsed and lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.